Report ID: 10325503 |
Published Date: 21 Oct 2022 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
Global Biological Drugs Market is estimated to reach $394 billion by 2024; growing at a CAGR of 10.3% from 2016 to 2024. Biological drugs are products manufactured by using microorganisms or plants or animal cells and are used for prevention, diagnosis and treatment of several diseases. These drugs are derived from several range of animals, humans or microorganisms by using biotechnology. For a positive outcome, biological products must remain persistent by quality and purity throughout the procedure. They are highly sensitive and can cause variations in the product even due to very minute changes during the process. Thereby, biologics must be produced under very controlled environment to ensure predictable results. Biological drugs are greatly used for the treatment of several serious and chronic illnesses such as cancer, ulcerative colitis, rheumatoid arthritis and other autoimmune diseases.
Increasing government initiatives supporting the development of biological drugs, rapid increase in geriatric population, growing commonness of chronic and lifestyle diseases and increasing investments on R&D are the factors boosting the growth of the global biological drugs market. Moreover, reduced price of drugs and technological advancements would provide several market opportunities in coming years. Though, adverse effects and high costs of these drugs might hamper the growth.
The global biological drugs market is segmented into product type and geography. By product type, the market is segmented into monoclonal antibody (Humira, Rituxan, Avastin, Lucentis, Remicade, Herceptin, And Others), therapeutic protein (Neulasta, Enbrel, Lantus, Avones, Novolog, Aranesp, Rebif, Humalog, Epogen, Victoza, Neupogen, Levemir, Betaseron, Eylea And Others), and vaccine (Prevnar 13, Varivax, Fluzone, Gardasil, Cervarix, And Others).
By geography, the market has been bifurcated into North America, Europe, Asia-Pacific, and Rest of the World (RoW). The U.S., Canada, Mexico are covered under North America wherein Europe covers UK, Germany, France Italy, and others. Asia-Pacific covers China, Japan, India, South Korea, and others. RoW covers South America, Middle East, and Africa.
They key companies operating in this market include Amgen Inc., Baxter International Inc., Eli Lilly and Co., Merck & Co., Inc., Bristol-Myers Squibb Company, Biogen Inc., GlaxoSmithKline Plc, Novartis AG, Pfizer Inc., and Abbott Laboratories, among others.
The key takeaways from the report:
The report will provide a detailed analysis of Global Biological Drugs Market with respect to major segments such as product type and geography
The report will include the qualitative and quantitative analysis with market estimation over 2015-2024 and compound annual growth rate (CAGR) between 2016 and 2024
Comprehensive analysis of market dynamics including factors and opportunities will be provided in the report
An exhaustive regional analysis of Global Biological Drugs Market from 2015 to 2024 has been included in the report
Profile of the key players in the Global Biological Drugs Market will be provided, which include key financials, product & services, new developments and business strategies
Scope of the Global Biological Drugs Market:
Product Type Segments
Monoclonal Antibody
Humira
Rituxan
Avastin
Lucentis
Remicade
Herceptin
Others
Therapeutic Protein
Neulasta
Enbrel
Lantus
Avones
Novolog
Aranesp
Rebif
Humalog
Epogen
Victoza
Neupogen
Levemir
Betaseron
Eylea
Others
Vaccine
Prevnar 13
Varivax
Fluzone
Gardasil
Cervarix
Others
Geography Segments
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Other
Asia-Pacific
India
China
Japan
South Korea
Others
RoW
South America
Middle East
Africa
呡
Why Choose Kenneth Research ?
-
Insight with Impact : We don’t just gather data — we uncover stories, trends, and opportunities that fuel business growth.
-
Experts Who Get It : Our team speaks your industry’s language and knows what really matters to your customers and market.
-
Custom-Built for You : Forget one-size-fits-all. We craft research and consulting solutions as unique as your business vision.
-
Partners, Not Just Providers : We work with you, not for you — collaborating closely to turn insights into smart, strategic moves.
-
Results That Speak : Our work powers brands, startups, and industry leaders alike — with a track record of ideas that work in the real world.
Report ID: 10325503 |
Published Date: 21 Oct 2022 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
